Literature DB >> 26831808

[Structure and Function of the Nuclear Receptor Constitutive Androstane Receptor].

Yoshio Inouye1.   

Abstract

Animal defense mechanisms against both endogenous and exogenous toxic compounds function mainly through receptor-type transcription factors, including the constitutive androstane receptor (CAR). Following xenobiotic stimulation, CAR translocates into the nucleus and transactivates its target genes including oxygenic and conjugative enzymes and transporters in hepatocytes. We identified subcellular localization signals in the rat CAR: two nuclear localization signals (NLS1 and 2); two nuclear export signals (NES1 and 2); and a cytoplasmic retention region. The nuclear import of CAR is regulated by the importin-Ran system and microtubule network. Five splice variants (SV1-5) were identified in rat liver in addition to wild-type CAR. When expressed in immortalized cells, their artificial transcripts were inactive as transcription factors. A CAR mutant with three consecutive alanine residues inserted into the ligand-binding domain of CAR showed ligand-dependent activation of target genes in immortalized cells, which is in marked contrast to the constitutive transactivating nature of wild-type CAR. Using this assay system, androstenol and clotrimazole, both of which are inverse agonists of CAR, were classified as an antagonist and weak agonist, respectively. A member of the DEAD box DNA/RNA helicase family (DP97) and protein arginine methyltransferase 5 (PRMT5) were found to be gene (or promotor)-specific coactivators of CAR. The expression of the CAR gene might be under the control of clock genes mediated by the nuclear receptor Rev-erb-α.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26831808     DOI: 10.1248/yakushi.15-00215

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  1 in total

1.  Induction of Constitutive Androstane Receptor during the Development of Oxidative Stress.

Authors:  A V Shchul'kin; Yu V Abalenikhina; A A Seidkulieva; A N Ryabkov; E N Yakusheva
Journal:  Bull Exp Biol Med       Date:  2021-10-09       Impact factor: 0.804

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.